$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
奥拉帕尼治疗HER-2阴性的转移性乳腺癌的疗效
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA突变的HER2阴性转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗BRCA突变转移性乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕尼治疗癌症的有效性和安全性:随机对照试验的meta分析
2025-10-19 11:44:20
Check Details
舒尼替尼治疗移性乳腺癌患者
2025-10-19 11:44:20
Check Details
奥拉帕尼改善乳腺癌患者生存期
2025-10-19 11:44:20
Check Details
拉帕替尼联合卡培他滨治疗乳腺癌
2025-10-19 11:44:20
Check Details
奥拉帕利治疗转移性乳腺癌
2025-10-19 11:44:20
Check Details
帕博西尼联合来曲唑治疗乳腺癌
2025-10-19 11:44:20
Check Details
吉西他滨与紫杉醇联合治疗乳腺癌
2025-10-19 11:44:20
Check Details
帕博西林联合来曲唑治疗乳腺癌的优势
2025-10-19 11:44:20
Check Details
舒尼替尼联合多西紫杉醇治疗晚期乳腺癌
2025-10-19 11:44:20
Check Details
1
2
...
1656
1657
1658
1659
1660
1661
1662
...
4163
4164
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Anamorelin (ADLUMIZ): GHS-R1a Agonist for Cancer Cachexia—Mechanism, Use, and Safety Boundaries
2
Vemurafenib Mechanism and Clinical Indications: BRAF V600E Mutant Melanoma and ECD Treatment
3
Ribociclib: Mechanism of Action and Approved Uses in Breast Cancer
4
Binimetinib + Encorafenib: Dual MEK/BRAF Targeting in BRAF+ Tumors
5
Neratinib Dosing: 240mg Start, Diarrhea Prophylaxis, Hepatic Adjustment
6
Selumetinib and KRAS Mutations: Where the MEK Inhibitor Actually Fits
7
Erdafitinib in Lung Squamous Cell Carcinoma: Indication Boundaries and FGFR Interpretation
8
Daraxonrasib (Rasonque): Chemical Identity and RAS Tri-Complex Mechanism
9
Tamoxifen and Feeling Older: Managing Hot Flashes, Fatigue, and Skin Changes
10
FDA Approves Pembrolizumab for TMB-H Solid Tumors: Threshold ≥13 mut/Mb, KEYNOTE-158 Data
11
Capmatinib for METex14 NSCLC: Test First, Monitor Toxicity
12
Ribociclib Still Allows Recurrence: HR+/HER2- Adjuvant and Advanced Use